News

In this interview with Shahriari at RAD 2025, she highlights some of the most significant burdens that patients and caregivers face with atopic dermatitis.

Investigators compared the efficacy of tirzepatide and liraglutide in lowering rates of all-cause mortality in patients with obesity and sleep apnea.

In this Q&A interview, Silverberg highlighted takeaways from his talk at RAD 2025 on recent FDA approvals for atopic dermatitis.

52-week data from the VALIANT program shed further light on the potential of pegcetacoplan in C3G and IC-MPGN.

Prespecified analysis of 320 patients in VISIONARY were presented at ERA 2025 Congress.

In this session at RAD 2025, Tiffany Mayo, MD, spoke to attendees about several examples of complex cases in atopic dermatitis and touched on hair loss concerns.

New research has indicated that glucagon-like peptide-1 receptor agonists result in lower all-cause mortality and risk of cardiovascular events in patients with concurrent sleep apnea and type 2 diabetes.

In this video segment, Kircik described the data highlighted in his JAK inhibitor-related presentation at RAD 2025.

This interview highlights the takeaways from Kircik’s talk at the 2025 RAD Conference regarding JAK inhibitor use and boxed warning concerns.

Brendon Neuen, MBBS, PhD, is joined by Rajiv Agarwal, MD, MS to explore the concept of simultaneous initiation of SGLT2i and nsMRA in CKD and T2D.

Compared to age-matched controls, women with premature menopause had greater risks of all-cause mortality and multiple cardiovascular complications.

Disrupted circadian rest-activity rhythms were tied to faster biological aging in older adults, independent of age, sex, or race, new study shows.

New data from a phase 2 and an OLE trial provide additional insight into the effects of iptacopan in IgA nephropathy.

Richard Lafeyette, MD, discusses his reaction to the phase 3 ORIGIN topline results and what it means for IgAN.

GLP-1 RAs, one of the most common medications for obesity and diabetes, have several inherent risks that are often overlooked in favor of their efficacy.

The month in review spotlights hepatic podcast episodes from HCPLive, new clinical trial data, and coverage from DDW.

Immunization is underused in IBD care despite high infection risks from immunosuppressants—early, proactive vaccination is essential for prevention.

Investigators compared the medications across various patient cohorts with different causes of anemia, finding evidence almost uniformly in favor of FCM.

UK study finds atopic conditions, especially anaphylaxis, significantly raise the risk of anxiety, depression, OCD, and other mental illnesses in primary care patients.

This video includes a discussion of different procedures designed to help treat patients with hidradenitis suppurativa (HS) and atopic dermatitis.

Combination therapy with finerenone and empagliflozin significantly reduces urinary albumin levels in CKD patients.

This recent study highlights the intricate variations between glaucoma cases, encouraging a more individual approach to analyzing treatment responses.

Jonathan Barratt, MD, PhD, offers perspective on how the 100-week data from ERA 25 inform the potential of zigakibart.

New 100-week data reveals zigakibart's significant efficacy and safety in reducing proteinuria for IgA nephropathy.

Get an overview of the top stories from May 2025 in endocrinology in our monthly recap!

Asthma and peanuts were identified as key risk factors for grade 4 anaphylaxis in a retrospective study, highlighting the need for tailored prevention.

Alkhouri reviews data from the trial’s open-label compensated MASH cirrhosis arm demonstrating resmetirom’s impact on liver stiffness and CSPH.